Berlin Heals Reveals Significant Two-Year Outcomes of C-MIC Therapy
Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC therapy.
Berlin Heals stands at the forefront of bioelectric medicine for heart failure treatment, recently announcing the release of important findings through a peer-reviewed study. Titled "Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot study," this research was published in the esteemed ESC Heart Failure journal.
This study offers critical insights from the long-term follow-up of patients who participated in the initial pilot trial of the Cardiac Microcurrent Implantable Device (C-MIC). Its purpose was to restore myocardial function specifically in chronic heart failure patients. The findings illustrate sustained clinical benefits even two years post-active therapy cessation, following the device's implantation.
Comprehensive Study Overview
The long-term assessment focused on seven patients with chronic heart failure (NYHA Class III, mean LVEF 31.7%). They were reassessed after completing a six-month pilot trial for various measures, including mortality, hospitalization rates, and device-related adverse events.
Key Findings of the Study
Significant outcomes from this two-year follow-up highlight the success of C-MIC therapy:
- Throughout the two years, no device-related adverse events occurred.
- LVEF enhancements of +11.6% at 6 months were maintained, now with a total improvement of +12.6% two years after device deactivation.
- The 6-minute walk distance (6MWD) increased by over 200 meters within 6 months, remaining about +191 meters above baseline two years later.
- Consistent improvements in NYHA functional class and SF-36 quality-of-life scores were documented.
- Only one patient required a reactivation of the C-MIC.
Clinical Insights and Future Directions
Prof. Dragana Kosevic, the study's primary author and Co-Principal Investigator, expressed excitement about the implications of these findings. "These results provide invaluable insights into the long-term potential of C-MIC therapy. It is particularly encouraging that improvements in cardiac function and overall patient wellbeing were sustained, even after the device had been switched off, indicating a possible disease-modifying impact."
In line with this sentiment, John Brumfield, CEO of Berlin Heals, emphasized how this study enhances their confidence in microcurrent therapy. "The publication and results signify both the safety and the longevity of impact from C-MIC, setting the groundwork for expansive clinical trials ahead."
Berlin Heals is actively broadening its clinical development strategy, currently engaged in the multicenter C-MIC III trial across various European countries, further advancing their mission in innovative heart failure interventions.
Frequently Asked Questions
What does the C-MIC device aim to do?
The C-MIC device strives to restore myocardial function in patients suffering from chronic heart failure.
Who led the recent study on C-MIC therapy?
The study was led by Prof. Dragana Kosevic, who serves as the first author and Co-Principal Investigator.
What are the safety results reported in the study?
Notably, no device-related adverse events were reported throughout the two-year follow-up period.
How did patients report their quality of life after the therapy?
Patients demonstrated consistent improvements in NYHA functional class and SF-36 quality-of-life scores over the assessed period.
What is the next step for Berlin Heals regarding clinical trials?
Berlin Heals is expanding its efforts through the multicenter C-MIC III trial, focusing on advancing heart failure treatment further.
